AU2795499A - Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment - Google Patents

Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment

Info

Publication number
AU2795499A
AU2795499A AU27954/99A AU2795499A AU2795499A AU 2795499 A AU2795499 A AU 2795499A AU 27954/99 A AU27954/99 A AU 27954/99A AU 2795499 A AU2795499 A AU 2795499A AU 2795499 A AU2795499 A AU 2795499A
Authority
AU
Australia
Prior art keywords
polyaspartate
polyglutamate
suramin
peg
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27954/99A
Inventor
Gregorz Czerwinski
Michael E. Jeffers
Christopher J. Michejda
George F Vande Woude
Craig P. Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2795499A publication Critical patent/AU2795499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
    • C09B69/106—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an azo dye
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
AU27954/99A 1998-02-26 1999-02-26 Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment Abandoned AU2795499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7599498P 1998-02-26 1998-02-26
US60075994 1998-02-26
PCT/US1999/004336 WO1999043311A2 (en) 1998-02-26 1999-02-26 Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment

Publications (1)

Publication Number Publication Date
AU2795499A true AU2795499A (en) 1999-09-15

Family

ID=22129246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27954/99A Abandoned AU2795499A (en) 1998-02-26 1999-02-26 Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment

Country Status (2)

Country Link
AU (1) AU2795499A (en)
WO (1) WO1999043311A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
EP1969031B1 (en) 2005-12-05 2009-06-03 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
GB2474809B (en) * 2008-08-04 2013-03-13 Sammy Opiyo Suramin amino salts for medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
EP0759467B1 (en) * 1995-07-24 2004-02-11 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor

Also Published As

Publication number Publication date
WO1999043311A2 (en) 1999-09-02
WO1999043311A3 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
PL351611A1 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
AU2206800A (en) Targeted molecular bar codes and methods for using the same
IL139286A0 (en) Polyol-ifn-beta conjugates, their preparation and use
MXPA02001508A (en) Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents.
PT1218378E (en) TERC-BUTYL (7-METHYL-IMIDAZO-1,2-A-PYRIDIN-3-YL) -AMINE DERIVATIVES
HUP0104167A3 (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
AU5589999A (en) Methods for the preparation of conjugated oligomers
AU4006800A (en) 1,2-dithiolane derivatives
IL146015A0 (en) Methods for producing 5'-nucleic acid-protein conjugates
HK1027141A1 (en) Beam supporter.
PL348668A1 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
AU2795499A (en) Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment
CA2351658A1 (en) Anticonvulsant derivatives useful in treating post traumatic stress disorder
AUPP373698A0 (en) Molecular coatings
CA2297149A1 (en) 13-deoxyanthracycline derivatives for treating cancer
HUP0102518A3 (en) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
AU7919100A (en) Clear hair-treatment agent
AU3196000A (en) 3,3'-diketotrehalose
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
HUP0201862A3 (en) Herbicidal tricyclic benzoylcyclohexanedione derivatives, preparation and use thereof
PL352760A1 (en) Oxathiepino[6,5-b
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase